1
|
Chávez-Gutiérrez L, Matta-Camacho E, Osuna J, Horjales E, Joseph-Bravo P, Maigret B, Charli JL. Homology modeling and site-directed mutagenesis of pyroglutamyl peptidase II. Insights into omega-versus aminopeptidase specificity in the M1 family. J Biol Chem 2006; 281:18581-90. [PMID: 16611635 DOI: 10.1074/jbc.m601392200] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Pyroglutamyl peptidase II (PPII), a highly specific membrane-bound omegapeptidase, removes N-terminal pyroglutamyl from thyrotropin-releasing hormone (<Glu-His-Pro-NH(2)), inactivating the peptide in the extracellular space. PPII and enzymes with distinct specificities such as neutral aminopeptidase (APN), belong to the M1 metallopeptidase family. M1 aminopeptidases recognize the N-terminal amino group of substrates or inhibitors through hydrogen-bonding to two conserved residues (Gln-213 and exopeptidase motif Glu-355 in human APN), whereas interactions involved in recognition of pyroglutamyl residue by PPII are unknown. In rat PPII, the conserved exopeptidase residue is Glu-408, whereas the other one is Ser-269. Given that variations in M1 peptidase specificity are likely due to changes in the catalytic region, we constructed three-dimensional models for the catalytic domains of PPII and APN. The models showed a salt bridge interaction between PPII-Glu-408 and PPII-Lys-463, whereas the equivalent APN-Glu-355 did not participate in a salt bridge. Docking of thyrotropin-releasing hormone in PPII model suggested that the pyroglutamyl residue interacted with PPII-Ser-269. According to our models, PPII-S269Q and -K463N mutations should leave Glu-408 in a physicochemical context similar to that found in M1 aminopeptidases; alternatively, PPII-S269E replacement might be sufficient to transform PPII into an aminopeptidase. These hypotheses were supported by site-directed mutagenesis; the mutants lost omegapeptidase but displayed alanyl-aminopeptidase activity. In conclusion, recognition of a substrate without an N-terminal charge requires neutralization of the aminopeptidase anionic binding site; furthermore, shortening of side chain at PPII-269 position is required for adjustment to the pyroglutamyl residue.
Collapse
Affiliation(s)
- Lucía Chávez-Gutiérrez
- Departamento de Genética del Desarrollo y Fisiología Molecular, Universidad Nacional Autónoma de México, 62271 Cuernavaca, Morelos, México
| | | | | | | | | | | | | |
Collapse
|
2
|
Irazusta J, Larrinaga G, González-Maeso J, Gil J, Meana JJ, Casis L. Distribution of prolyl endopeptidase activities in rat and human brain. Neurochem Int 2002; 40:337-45. [PMID: 11792464 DOI: 10.1016/s0197-0186(01)00078-x] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Prolyl endopeptidase is a proteolytic enzyme which could have a neuropeptide catabolising role in the central nervous system. Although prolyl endopeptidase has been described as a cytosolic enzyme, it has become clear that it can also be found in particulate form. The regional and subcellular distribution of this enzyme was evaluated in rat and human brain. The activity of the enzyme was higher in the human than in the rat brain. In the human brain, the activity levels of both soluble and particulate prolyl endopeptidase were the highest in frontal, parietal and occipital cortices and the lowest in the cerebellum. In the rat brain, the regional distribution of the enzyme was more homogeneous. The activity in all the areas of the central nervous system is higher than in peripheral tissues. Subcellular distribution of the enzyme in the brain indicates that prolyl endopeptidase was higher in the cytosolic fraction than in the particulate fractions. The particulate form was enriched in the synaptosomal and the myelinic membranes. The high activity of prolyl endopeptidase in the human cortex suggests that prolyl endopeptidase could play a role in the functions of this brain area.
Collapse
Affiliation(s)
- Jon Irazusta
- Department of Physiology, Medical School, University of the Basque Country, Leioa, P.O. Box 699, 48,080 Bilbao, Spain.
| | | | | | | | | | | |
Collapse
|
3
|
Shinoda M, Miyazaki A, Toide K. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and on cholinergic and peptidergic neurons in rats with ibotenate-induced lesions of the nucleus basalis magnocellularis. Behav Brain Res 1999; 99:17-25. [PMID: 10512568 DOI: 10.1016/s0166-4328(98)00005-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
We conducted behavioral and neurochemical studies of a novel prolyl endopeptidase inhibitor, (S)2-[[(S)-2-(hydroxyacetyl)-1pyrrolidinyl]carbonyl]-N-(phenylmeth yl)-1-pyrrolidine-carboxamide (JTP-4819), in rats with lesions of the nucleus basalis magnocellularis (NBM-lesioned rats) induced by ibotenate. Administration of JTP-4819 (1 and 3 mg/kg, p.o.), on and after the 8th day, significantly shortened the escape latency in the Morris water maze as compared to the vehicle-treated group. JTP-4819 also significantly increased the path length in the quadrant with the platform removed in the spatial probe trial. Neurochemical studies of brains removed after the Morris water maze task showed that choline acetyltransferase activity in the cerebral cortex, but not the hippocampus, was significantly reduced by NBM lesioning, while there were no changes of muscarinic M1 receptor binding activity detected using [3H]pirenzepine. JTP-4819 had almost no effect on these cholinergic parameters in NBM-lesioned rats. Substance P-like immunoreactivity (LI), thyrotropin-releasing hormone (TRH)-LI, and arginine-vasopressin-LI were not significantly changed in the cerebral cortex and hippocampus of NBM-lesioned rats as compared to sham-operated rats. However, these neuropeptide levels were significantly increased in both brain regions by repeated administration of JTP-4819 (1, 3 and/or 10 mg/kg, p.o.). These results suggest that JTP-4819 ameliorated memory impairment due to NBM lesioning by potentiating SP, TRH and AVPergic neurons secondary to PEP inhibition.
Collapse
Affiliation(s)
- M Shinoda
- Central Pharmaceutical Research Institute, Japan Tobacco, Takatsuki, Osaka
| | | | | |
Collapse
|
4
|
Toide K, Shinoda M, Miyazaki A. A novel prolyl endopeptidase inhibitor, JTP-4819--its behavioral and neurochemical properties for the treatment of Alzheimer's disease. Rev Neurosci 1998; 9:17-29. [PMID: 9683325 DOI: 10.1515/revneuro.1998.9.1.17] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Formation of beta-amyloid and neurofibrillary tangles in the brain due to genetic or other factors is the most frequent cause of Alzheimer's disease. In addition, marked reduction of certain brain neuropeptide levels is a consistent finding in patients with Alzheimer's disease, together with the deterioration of cholinergic neurons. Currently, there is great demand for the development of new drugs to improve memory deficits or to delay the neurodegenerative process in conditions such as Alzheimer's disease. In this report, the pharmacological actions of JTP-4819, a novel specific prolyl endopeptidase (PEP) inhibitor devised for the treatment of Alzheimer's disease, are reviewed with respect to its effects on PEP activity, neuropeptidergic and cholinergic neurons, and memory-related behavior in rats. We also discuss the possible beneficial effect of JTP-4819 on beta-amyloid metabolism and its potential neuroprotective properties.
Collapse
Affiliation(s)
- K Toide
- Central Pharmaceutical Research Institute, Japan Tobacco Inc., Takatsuki, Osaka
| | | | | |
Collapse
|
5
|
Toide K, Shinoda M, Fujiwara T, Iwamoto Y. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. Pharmacol Biochem Behav 1997; 56:427-34. [PMID: 9077579 DOI: 10.1016/s0091-3057(96)00238-9] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The effects of a novel prolyl endopeptidase inhibitor (PEP), (S)-2-[[(S)-2-(hydroxyacetyl)-1-pyrrolidinyl]carbonyl]-N-(phenylmethyl)- 1-pyrrolidinecar-boxamide (JTP-4819), on performance of the Morris water maze task and on central cholinergic function were investigated in aged rats. Spatial memory (escape latency, path length, and swimming speed to the platform) was impaired in aged rats performing the Morris water maze task when compared to young rats. Administration of JTP-4819 (1 mg/kg, p.o.) for 14 days improved this memory deficit in aged rats, as shown by the decrease in escape latency and path length. In addition, when JTP-4819 (at doses of 1 and 3 mg/kg, p.o.) was administered for 3 wk, it reversed the age-related increase of ChAT activity in the cerebral cortex and the decrease of 3H-choline uptake in the hippocampus. These data suggest that JTP-4819 ameliorates age-related impairment of spatial memory and partly reverses central cholinergic dysfunction, possibly due to the enhancement of neuropeptide function by inhibition of PEP mediated degradation of substance P, arginine-vasopressin, and thyrotropin-releasing hormone.
Collapse
Affiliation(s)
- K Toide
- Central Pharmaceutical Research Institute, Japan Tobacco Inc., Takatsuki, Osaka
| | | | | | | |
Collapse
|
6
|
Toide K, Shinoda M, Iwamoto Y, Fujiwara T, Okamiya K, Uemura A. A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Behav Brain Res 1997; 83:147-51. [PMID: 9062674 DOI: 10.1016/s0166-4328(97)86059-7] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The pharmacological actions of JTP-4819, a new prolyl endopeptidase (PEP) inhibitor targeted for the treatment of Alzheimer's disease, are reviewed with respect to its effects on PEP activity, brain neurotransmitters, and memory-related behaviour in rats. JTP-4819 was shown to be a very potent and specific inhibitor of PEP. At nanomolar concentration, JTP-4819 inhibited the degradation of substance P, arginine-vasopressin, and thyrotropin-releasing hormone by PEP in supernatants of the rat cerebral cortex and hippocampus. Repeated administration of JTP-4819 reversed the aging-induced decrease in brain substance P-like and thyrotropin-releasing hormone-like immunoreactivity, suggesting that this drug may be able to improve the imbalance of peptidergic neuronal systems that develops with senescense by inhibiting PEP activity. JTP-4819 increased acetylcholine release from the frontal cortex and hippocampus, regions closely associated with memory, in both young and aged rats. In addition, it improved performance in several memory and learning-related tests (e.g., the Morris water maze task in aged or MCA-occluded rats and the passive avoidance test). This memory-enhancing effect of JTP-4819 may result from prevention of the metabolic degradation of brain neuropeptides by PEP as well as from the enhancement of acetylcholine release. Taken together, these unique and potent pharmacological actions of JTP-4819 suggest that it may have the potential to be used for treating Alzheimer's disease.
Collapse
Affiliation(s)
- K Toide
- Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan
| | | | | | | | | | | |
Collapse
|
7
|
Toide K, Shinoda M, Iwamoto Y, Fujiwara T, Abe H, Uchida I. A Novel Prolyl Endopeptidase Inhibitor, JTP-4819, for the Treatment of Alzheimer's Disease: Review of Preclinical Pharmacology. CNS DRUG REVIEWS 1996. [DOI: 10.1111/j.1527-3458.1996.tb00306.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
8
|
Shinoda M, Matsuo A, Toide K. Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion. Eur J Pharmacol 1996; 305:31-8. [PMID: 8813528 DOI: 10.1016/0014-2999(96)00173-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We studied behavioral and pharmacological effects of a novel prolyl endopeptidase inhibitor, (S)-2-[[(S)-2-(hydroxyacetyl)- 1-pyrrolidinyl]carbonyl]-N-(phenylmethyl)-1-pyrrolidine-car boxamide (JTP-4819), in rats with middle cerebral artery occlusion. Administration of JTP-4819 (0.1 and 1 mg/kg p.o for 7 days) significantly prolonged passive avoidance latency, while the latency of rats with middle cerebral artery occlusion receiving the vehicle was significantly shorter than that of sham-operated rats. The prolonged escape latency in the Morris water maze task in rats with middle cerebral artery occlusion was also significantly reduced by administration of JTP-4819 (0.3 and 1 mg/kg p.o.). Interestingly, administration of JTP-4819 (0.3-3 mg/kg p.o. for 15 days) restored the decreased cortical thyrotropin-releasing hormone (TRH)-like immunoreactivity content of rats with middle cerebral artery occlusion but did not affect the cortical and hippocampal substance P- or arginine vasopressin-like immunoreactivity content. These results suggest that JTP-4819 ameliorates memory impairment due to middle cerebral artery occlusion by restoring the cortical TRH content.
Collapse
Affiliation(s)
- M Shinoda
- Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan
| | | | | |
Collapse
|
9
|
Toide K, Fujiwara T, Iwamoto Y, Shinoda M, Okamiya K, Kato T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 1996; 353:355-62. [PMID: 8692293 DOI: 10.1007/bf00168640] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The effect of a novel prolyl endopeptidase (PEP) inhibitor, (S)-2-[[(S)-2-(hydroxyacetyl)-1-pyrrolidinyl] carbonyl]-N-(phenylmethyl)-1-pyrrolidine-carboxamide (JTP-4819), on neuropeptide metabolism was investigated in the rat brain. JTP-4819 exhibited a strong in vitro inhibitory effect on cortical and hippocampal PEP activity, with the IC50 values being approximately 0.58 +/- 0.02 and 0.61 +/- 0.06 nM, respectively. JTP-4819 also inhibited the in vitro degradation of substance P (SP), arginine-vasopressin (AVP), and thyrotropin-releasing hormone (TRH) by rat brain supernatants, with the IC50 values being respectively 3.4, 2.1, and 1.4 nM in the cerebral cortex and 3.3, 2.8, and 1.9 nM in the hippocampus. Oral administration of JTP-4819 at doses of 1 and 3 mg/kg increased SP-like immunoreactivity (LI) and AVP-LI in the cerebral cortex. JTP-4819 also increased hippocampal SP-LI and AVP-LI at doses of 1 and 3 mg/kg, as well as hippocampal TRH-LI at a dose of 3 mg/kg. These findings suggest that JTP-4819 inhibited the degradation of SP, AVP, and TRH in the rat brain secondary to the inhibition of PEP, and thus increased cortical and hippocampal SP-LI and AVP-LI as well as hippocampal TRH-LI.
Collapse
Affiliation(s)
- K Toide
- Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan
| | | | | | | | | | | |
Collapse
|
10
|
Shinoda M, Okamiya K, Toide K. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on thyrotropin-releasing hormone-like immunoreactivity in the cerebral cortex and hippocampus of aged rats. JAPANESE JOURNAL OF PHARMACOLOGY 1995; 69:273-6. [PMID: 8699636 DOI: 10.1254/jjp.69.273] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
We investigated the effects of a novel prolyl endopeptidase inhibitor, JTP-4819 ((S)-2-[[(S)-2-(hydroxyacetyl)-1-pyrrolidinyl]carbonyl]-N- (phenylmethyl)-1-pyrrolidinecarboxamide), on thyrotropin-releasing hormone (TRH)-like immunoreactivity (TRH-LI) in the cerebral cortex and hippocampus of aged rats. The TRH-LI content of both brain regions in aged rats was significantly lower than that in young rats. A single oral dose of JTP-4819 (3 mg/kg) restored the cortical TRH-LI content in aged rats, while doses of 0.3-3 mg/kg restored it in the hippocampus. Repeated oral administration of JTP-4819 at a dose of 1 mg/kg for 21 days produced a significant increase of TRH-LI in the cerebral cortex, while it did so in the hippocampus at doses of 0.3 and 1 mg/kg. Our findings suggest that JTP-4819 may improve the functioning of TRHergic neurons, which deteriorate with senescence.
Collapse
Affiliation(s)
- M Shinoda
- Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan
| | | | | |
Collapse
|
11
|
Toide K, Shinoda M, Takase M, Iwata K, Yoshida H. Effects of a novel thyrotropin-releasing hormone analogue, JTP-2942, on extracellular acetylcholine and choline levels in the rat frontal cortex and hippocampus. Eur J Pharmacol 1993; 233:21-8. [PMID: 8472746 DOI: 10.1016/0014-2999(93)90344-h] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The effects of a novel thyrotropin-releasing hormone (TRH) analogue, N alpha-[(1S,2R)-2-methyl-4-oxocyclopentanecarbonyl]-L-histidyl-L-pr olinamide (JTP-2942) on acetylcholine (ACh) release and on the extracellular choline level were investigated in rat frontal cortex and hippocampus by microdialysis, and were compared with effects of TRH. JTP-2942 (0.3 mg/kg i.p.) produced a marked (> 300%) and persistent increase of ACh release in both the frontal cortex and hippocampus, while TRH (3 mg/kg i.p.) caused a significant but transient increase of ACh to about 200% in the frontal cortex. Both drugs significantly decreased the choline levels in both brain regions. Investigation of the effects of JTP-2942 (0.001-1 mM) and TRH (1 and 10 mM) on ACh release and choline levels when perfused through the dialysis probe revealed that JTP-2942 had a greater effect than TRH in both the frontal cortex and the hippocampus. The action of JTP-2942 was about 1000-fold more potent than that of TRH in both brain regions. Oral administration of JTP-2942 at a dose of 10 mg/kg markedly and persistently increased the release of ACh and at doses of 1-10 mg/kg decreased the extracellular choline level in the frontal cortex and hippocampus. These results also suggest that JTP-2942 has some selectivity for the hippocampus compared to the frontal cortex after both systemic administration and local injection. The increase of ACh release caused by JTP-2942 was completely antagonized by perfusion with tetrodotoxin (TTX, 1 microM), suggesting that the action of JTP-2942 on cholinergic neurons was mediated via neuronal activity.
Collapse
Affiliation(s)
- K Toide
- Department of Pharmacology, Japan Tobacco Inc., Kanagawa
| | | | | | | | | |
Collapse
|
12
|
Elmore MA, Griffiths EC, O'Connor B, O'Cuinn G. Further characterization of the substrate specificity of a TRH hydrolysing pyroglutamate aminopeptidase from guinea-pig brain. Neuropeptides 1990; 15:31-6. [PMID: 1970134 DOI: 10.1016/0143-4179(90)90157-t] [Citation(s) in RCA: 32] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
In this study the substrate specificity of a pyroglutamate aminopeptidase from synaptosomal membranes of guinea-pig brain was investigated. The enzyme was found to be specific for tripeptides, tripeptide-amides and tetrapeptides which possess the N-terminal sequence Glp-His and as such is specific for Thyrotropin Releasing Hormone or only very closely related peptides. The enzyme was found not to hydrolyse a number of analogues of Thyrotropin Releasing Hormone which have been shown to have therapeutical value in certain neuronal disorders.
Collapse
Affiliation(s)
- M A Elmore
- Department of Biochemistry, University College, Galway, Ireland
| | | | | | | |
Collapse
|
13
|
PRASAD CHANDAN. Neurobiology of Cyclo(His-Pro). Ann N Y Acad Sci 1989. [DOI: 10.1111/j.1749-6632.1989.tb54492.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
Affiliation(s)
- C Prasad
- Department of Medicine, Louisiana State University Medical Center, New Orleans 70112
| |
Collapse
|
15
|
TACHÉ YVETTE, STEPHENS ROBERTL, ISHIKAWA TOSHIO. Central Nervous System Action of TRH to Influence Gastrointestinal Function and Ulceration. Ann N Y Acad Sci 1989. [DOI: 10.1111/j.1749-6632.1989.tb54495.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
KELLY JULIEA, GRIFFITHS EC. A Comparison of TRH and Analogue Degradation by Rat Spinal Cord, Brain Stem, and Cortex. Ann N Y Acad Sci 1989. [DOI: 10.1111/j.1749-6632.1989.tb46698.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
17
|
Taché Y, Stephens RL, Ishikawa T. Central nervous system action of TRH to influence gastrointestinal function and ulceration. Ann N Y Acad Sci 1989; 553:269-85. [PMID: 2497674 DOI: 10.1111/j.1749-6632.1989.tb46649.x] [Citation(s) in RCA: 57] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
There is clear evidence in rats that TRH acts in the brain to stimulate gastric acid, pepsin, and serotonin secretion, mucosal blood flow, contractility, emptying, and ulceration through activation of parasympathetic outflow to the stomach (TABLE 3). A number of TRH analogues, including some devoid of TSH-releasing activity, mimic the effects of TRH. The most sensitive TRH sites of action to elicit gastric acid secretion and motility are located in the dorsal vagal complex and include the dorsal vagal, nucleus tractus solitarius, and nucleus ambiguus. The gastrointestinal tract is one of the most responsive visceral systems to the central effects of TRH, because doses in the range of 1-10 pmol in the dorsal vagal complex stimulate gastric function, whereas stimulation of cardiovascular and respiratory function on microinjection of the brainstem nuclei requires higher doses. Although fewer investigations have been carried out in other species, evidence from the available data clearly indicates that TRH acts in the brain to increase gastric secretion and motility in the rabbit, sheep, and cat. Lack of stimulation of gastric acid secretion after third ventricle injection in the dog may be related to species difference or to rapid degradation of the peptide before it reaches its site of action. TRH acts centrally to stimulate gastric function and also intestinal secretion, motility, and transit as reported mostly in rabbits (TABLE 3). TRH produces enteropooling and release of serotonin in portal blood, increases duodenal and intestinal contractility and colonic transit, and elicits diarrhea. All these effects were shown to be vagally mediated. Stimulation of intestinal motility and transit by central injection of TRH has been observed in rats and sheep. The biological activity of centrally injected TRH is well correlated with the presence of TRH immunoreactivity and receptors in the dorsal vagal complex containing afferent and efferent connections to the stomach. Moreover, endogenous release of brain TRH in rats mimics the stimulatory effect of centrally injected TRH on gastric function. Although the lack of a specific TRH antagonist has hampered assessment of the physiological role of TRH, converging neuropharmacological, neuroanatomical, and physiological findings support the concept that TRH in the dorsal vagal complex may play a physiological role in the vagal regulation of gastrointestinal function.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- Y Taché
- Center for Ulcer Research and Education, Veterans Administration Medical Center, Los Angeles, California
| | | | | |
Collapse
|
18
|
KELLY JULIEA, GRIFFITHS EC. A Comparison of TRH and Analogue Degradation by Rat Spinal Cord, Brain Stem, and Cortex. Ann N Y Acad Sci 1989. [DOI: 10.1111/j.1749-6632.1989.tb54544.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
19
|
GRIFFITHS EC, HALL TR, CHEUNG A, KELLY JA. GH Release from Avian Pituitary in Vitro and in Vivo by TRH Analogues. Ann N Y Acad Sci 1989. [DOI: 10.1111/j.1749-6632.1989.tb54535.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
GRIFFITHS EC, HALL TR, CHEUNG A, KELLY JA. GH Release from Avian Pituitary in Vitro and in Vivo by TRH Analogues. Ann N Y Acad Sci 1989. [DOI: 10.1111/j.1749-6632.1989.tb46689.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Turner JG, Schwartz TM, Brooks BR. Rapid separation of tritiated thyrotropin-releasing hormone and its catabolic products from mouse and human central nervous system tissues by high-performance liquid chromatography with radioactive flow detection. JOURNAL OF CHROMATOGRAPHY 1989; 487:275-86. [PMID: 2498373 DOI: 10.1016/s0378-4347(00)83037-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Reversed-phase high-performance liquid chromatography with radioactive flow detection was utilized to investigate the catabolism of thyrotropin-releasing hormone (TRH) in central nervous system (CNS) tissues. Two different column/gradient solvent systems were tested: (1) octadecylsilane (ODS) with an acetic acid-acetonitrile gradient and (2) poly(styrenedivinylbenzene) (PRP-1) with a trifluoroacetic acid-acetonitrile gradient. Both systems used 1-hexanesulfonic acid as the second ion-pairing reagent and yielded excellent separation of TRH and its catabolic products, TRH acid, cyclo(histidyl-proline), histidyl-proline, proline, and prolinamide, produced in CNS tissue homogenates. The PRP-1 column with a trifluoroacetic acid-acetonitrile solvent system produced a better and more reproducible separation of TRH catabolic products than the ODS column with the acetic acid-acetonitrile solvent system. This PRP-1 technique was utilized to demonstrate different rates and products of TRH catabolism in mouse and human spinal cord compared with cerebral cortex.
Collapse
Affiliation(s)
- J G Turner
- Neurology and Research Services, William S. Middleton Memorial VA Hospital, Madison, WI 53705
| | | | | |
Collapse
|
22
|
Guiloff RJ, Stålberg E, Eckland DJ, Lightman SL. Electrophysiological observations in patients with motor neuron disease receiving a thyrotropin releasing hormone analogue (RX77368). J Neurol Neurosurg Psychiatry 1987; 50:1633-40. [PMID: 3125307 PMCID: PMC1032605 DOI: 10.1136/jnnp.50.12.1633] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Twenty nine patients with motor neuron disease receiving a thyrotropin releasing hormone analogue showed acute 25-30% increase in mean corrected fibre density and mean macro EMG median amplitude and area in brachial biceps muscle. The data are consistent with a direct or indirect action of the drug on anterior horn cells.
Collapse
Affiliation(s)
- R J Guiloff
- Department of Neurology, Westminster Hospital, Charing Cross and Westminster Medical School, London, UK
| | | | | | | |
Collapse
|
23
|
Guiloff RJ, Eckland DJ, Demaine C, Hoare RC, MacRae KD, Lightman SL. Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease. J Neurol Neurosurg Psychiatry 1987; 50:1359-70. [PMID: 3119776 PMCID: PMC1032465 DOI: 10.1136/jnnp.50.10.1359] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Twenty five patients with motor neuron disease completed a double blind randomised cross over trial of RX77368, a stabilised TRH analogue, iv over 2 hours against saline. Temporary improvement in bulbar symptoms including speech, respiratory parameters, tongue movements and swallowing were seen. Fasciculations increased and spasticity decreased. Change in muscle force with drug was different from placebo but both increase and decrease in force were seen and did not result in detectable changes in function. Side effects were clinically significant in 50% of the patients and cleared within 12 hours. Prolonged rise of thyroxine and an increase in plasma levels of prolactin, thyroid stimulating hormone and growth hormone were seen and followed characteristic patterns.
Collapse
Affiliation(s)
- R J Guiloff
- Department of Neurology and Medicine, Charing Cross and Westminster Medical School, Westminster Hospital, London, UK
| | | | | | | | | | | |
Collapse
|
24
|
Observations on the Clinical Assessment of Patients with Motor Neuron Disease: Experience with a TRH Analogue. Neurol Clin 1987. [DOI: 10.1016/s0733-8619(18)30941-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
25
|
POSTER COMMUNICATIONS. Br J Pharmacol 1986. [DOI: 10.1111/j.1476-5381.1986.tb14741.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|